Ирландия - английский - HPRA (Health Products Regulatory Authority)

bayer plc - heparinoid hyaluronidase - ointment - 5000/15000 %v/v

Ирландия - английский - HPRA (Health Products Regulatory Authority)

bayer plc - heparinoid hyaluronidase - ointment - 5000/15000 %v/v

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

bayer new zealand limited - heparinoids 50 hdbu/g; hyaluronidase 150 iu/g - topical ointment - active: heparinoids 50 hdbu/g hyaluronidase 150 iu/g

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - heparinoid - cutaneous ointment - 8mg/1gram

Саудовская Аравия - английский - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer pharma ag, germany - heparinoid, hyaluronidase - ointment

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - heparinoid 5000 hdb-e/100g - 5000 hdb-e/100g

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - heparinoid 0.8 % - 0.8%

Бельгия - английский - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - lawsonia intracellularis (inactivated) >= 5323 u/dose - lyophilisate and solvent for emulsion for injection - lawsonia intracellularis inactivated - lawsonia - pig

Бельгия - английский - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - lawsonia intracellularis (inactivated) >= 5323 u/dose - lyophilisate and solvent for emulsion for injection - lawsonia intracellularis inactivated - lawsonia - pig

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glibenclamide, quantity: 5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; pregelatinised maize starch; lactose monohydrate; purified talc; maize starch - daonil and semi-daonil are indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2) whose hyperglycaemia cannot be controlled by diet alone. because of its broad and predictable action, daonil and semi-daonil are often suitable for the management of patients who have failed to respond to other oral antidiabetics.,in initiating treatment for non-insulin-dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment programme fails to reduce symptoms and/or blood glucose the use of an oral sulphonylurea should be considered. use of daonil and semi-daonil must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.